indigestion glp-1 Managing GLP-1/GIP side effects with diet and lifestyle Common GLP-1 Weight-loss Side Effects

The Medical Letters Post A New Indication for Semaglutide (Wegovy) The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight

Summary: Plasma donation eligibility whilst taking Wegovy (semaglutide) is determined by NHS Blood and Transplant on an individual basis, considering the medication, underlying health conditions, and current wellbeing

E.DavidsonT

Panagaki T, Gengler S, Hlscher C

GLP-1 users have reported a mouthful of problems, including dry mouth, bad breath, gum disease and tooth decay

After 68 weeks, teens taking the medication had a 16.1% reduction in BMI, compared to just 0.6% in the placebo group